Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 66-73

  Brauer, Patrick M ^a   Tyner, Angela L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Breast cancer; BRK; Colon cancer; Epithelia; PTK6; Sik; Tyrosine kinase

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB; LAPATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; STAT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; ENZYME SPECIFICITY; EPITHELIUM TUMOR; GENE STRUCTURE; HEAD AND NECK CANCER; HUMAN; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 77953704990     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.02.003     Document Type: Review

References (109)

1. Lee S.T., Strunk K.M., Spritz R.A. A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene 1993, 8:3403-3410.
2. Mitchell P.J., Barker K.T., Martindale J.E., Kamalati T., Lowe P.N., Page M.J., Gusterson B.A., Crompton M.R. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994, 9:2383-2390.
3. Siyanova E.Y., Serfas M.S., Mazo I.A., Tyner A.L. Tyrosine kinase gene expression in the mouse small intestine. Oncogene 1994, 9:2053-2057.
4. Brauer P.M., Tyner A.L. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle 2009, 8:2728-2732.
5. Kohmura N., Yagi T., Tomooka Y., Oyanagi M., Kominami R., Takeda N., Chiba J., Ikawa Y., Aizawa S. A novel nonreceptor tyrosine kinase, Srm: cloning and targeted disruption. Mol. Cell Biol. 1994, 14:6915-6925.
6. Kawachi Y., Nakauchi H., Otsuka F. Isolation of a cDNA encoding a tyrosine kinase expressed in murine skin. Exp. Dermatol. 1997, 6:140-146.
7. Neet K., Hunter T. Vertebrate non-receptor protein-tyrosine kinase families. Genes Cells 1996, 1:147-169.
8. Mitchell P.J., Barker K.T., Shipley J., Crompton M.R. Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. Oncogene 1997, 15:1497-1502.
9. Serfas M.S., Tyner A.L. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol. Res. 2003, 13:409-419.
10. D'Aniello S., Irimia M., Maeso I., Pascual-Anaya J., Jimenez-Delgado S., Bertrand S., Garcia-Fernandez J. Gene expansion and retention leads to a diverse tyrosine kinase superfamily in amphioxus. Mol. Biol. Evol. 2008, 25:1841-1854.
11. Park S.H., Lee K.H., Kim H., Lee S.T. Assignment of the human PTK6 gene encoding a non-receptor protein tyrosine kinase to 20q13.3 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 1997, 77:271-272.
12. Llor X., Serfas M.S., Bie W., Vasioukhin V., Polonskaia M., Derry J., Abbott C.M., Tyner A.L. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin. Cancer Res. 1999, 5:1767-1777.
13. Lee H., Kim M., Lee K.H., Kang K.N., Lee S.T. Exon-intron structure of the human PTK6 gene demonstrates that PTK6 constitutes a distinct family of non-receptor tyrosine kinase. Mol Cells 1998, 8:401-407.
14. Kang K.N., Kim M., Pae K.M., Lee S.T. Characterization of the 5'-flanking region of the human PTK6 gene. Biochim. Biophys. Acta 2002, 1574:365-369.
15. Simmen F.A., Xiao R., Velarde M.C., Nicholson R.D., Bowman M.T., Fujii-Kuriyama Y., Oh S.P., Simmen R.C. Dysregulation of intestinal crypt cell proliferation and villus cell migration in mice lacking Kruppel-like factor 9. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1757-G1769.
16. Qiu H., Miller W.T. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. J. Biol. Chem. 2002, 277:34634-34641.
17. Kim H., Lee S.T. An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6. J. Biol. Chem. 2005, 280:28973-28980.
18. Derry J.J., Richard S., Valderrama Carvajal H., Ye X., Vasioukhin V., Cochrane A.W., Chen T., Tyner A.L. Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. Mol. Cell. Biol. 2000, 20:6114-6126.
19. Kim H.I., Jung J., Lee E.S., Kim Y.C., Lee W.P., Lee S.T. Molecular dissection of the interaction between the SH3 domain and the SH2-Kinase Linker region in PTK6. Biochem. Biophys. Res. Commun. 2007, 362:829-834.
20. Ko S., Ahn K.E., Lee Y.M., Ahn H.C., Lee W. Structural basis of the auto-inhibition mechanism of nonreceptor tyrosine kinase PTK6. Biochem. Biophys. Res. Commun. 2009, 384:236-242.
21. Koo B.K., Kim M.H., Lee S.T., Lee W. Purification and spectroscopic characterization of the human protein tyrosine kinase-6 SH3 domain. J. Biochem. Mol. Biol. 2002, 35:343-347.
22. Qiu H., Miller W.T. Role of Brk SH3 domain in substrate recognition. Oncogene 2004, 23:2216-2223.
23. Qiu H., Zappacost F., Su W., Annan R.S., Miller W.T. Interaction between Brk kinase and insulin receptor substrate-4. Oncogene 2005, 24:5656-5664.
24. Lukong K.E., Huot M.E., Richard S. BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest. Cell Signal. 2009, 21:1415-1422.
25. Hong E., Shin J., Bang E., Kim M.H., Lee S.T., Lee W. Complete sequence-specific 1H, 13C and 15N resonance assignments of the human PTK6 SH2 domain. J. Biomol. NMR 2001, 19:291-292.
26. Hong E., Shin J., Kim H.I., Lee S.T., Lee W. Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain. J. Biol. Chem. 2004, 279:29700-29708.
27. Vasioukhin V., Tyner A.L. A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 1997, 94:14477-14482.
28. Mitchell P.J., Sara E.A., Crompton M.R. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 2000, 19:4273-4282.
29. Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., Lange C.A. Regulated association of protein kinase b/akt with breast tumor kinase. J. Biol. Chem. 2005, 280:1982-1991.
30. Palka-Hamblin H.L., Gierut J.J., Bie W., Brauer P.M., Zheng Y., Asara J.M., Tyner A.L. Identification of {beta}-catenin as a target of the intracellular tyrosine kinase PTK6. J. Cell Sci. 2010, 123:236-245.
31. Lukong K.E., Richard S. Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell. Signal. 2008, 20:432-442.
32. Shen C.H., Chen H.Y., Lin M.S., Li F.Y., Chang C.C., Kuo M.L., Settleman J., Chen R.H. Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res. 2008, 68:7779-7787.
33. Coyle J.H., Guzik B.W., Bor Y.C., Jin L., Eisner-Smerage L., Taylor S.J., Rekosh D., Hammarskjold M.L. Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK. Mol. Cell. Biol. 2003, 23:92-103.
34. Lukong K.E., Larocque D., Tyner A.L., Richard S. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J. Biol. Chem. 2005, 280:38639-38647.
35. Aubele M., Walch A.K., Ludyga N., Braselmann H., Atkinson M.J., Luber B., Auer G., Tapio S., Cooke T., Bartlett J.M. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br. J. Cancer 2008, 99:1089-1095.
36. Haegebarth A., Heap D., Bie W., Derry J.J., Richard S., Tyner A.L. The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J. Biol. Chem. 2004, 279:54398-54404.
37. Ikeda O., Miyasaka Y., Sekine Y., Mizushima A., Muromoto R., Nanbo A., Yoshimura A., Matsuda T. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem. Biophys. Res. Commun. 2009, 384:71-75.
38. Liu L., Gao Y., Qiu H., Miller W.T., Poli V., Reich N.C. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006, 25:4904-4912.
39. Weaver A.M., Silva C.M. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res. 2007, 9:R79.
40. Shin D.S., Kim Y.G., Kim E.M., Kim M., Park H.Y., Kim J.H., Lee B.S., Kim B.G., Lee Y.S. Solid-phase peptide library synthesis on HiCore resin for screening substrate specificity of Brk protein tyrosine kinase. J. Comb. Chem. 2008, 10:20-23.
41. Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., Edwards D.R. Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol. Cancer Res. 2008, 6:383-394.
42. Kamalati T., Jolin H.E., Mitchell P.J., Barker K.T., Jackson L.E., Dean C.J., Page M.J., Gusterson B.A., Crompton M.R. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J. Biol. Chem. 1996, 271:30956-30963.
43. Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M., Miller W.T., Muthuswamy S.K. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc. Natl. Acad. Sci. USA 2008, 105:12463-12468.
44. Mosnier J.F., Jarry A., Bou-Hanna C., Denis M.G., Merlin D., Laboisse C.L. ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Lab. Invest. 2006, 86:1064-1073.
45. Charrier-Hisamuddin L., Laboisse C.L., Merlin D. ADAM-15: a metalloprotease that mediates inflammation. FASEB J. 2008, 22:641-653.
46. Kamalati T., Jolin H.E., Fry M.J., Crompton M.R. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000, 19:5471-5476.
47. Ostrander J.H., Daniel A.R., Lofgren K., Kleer C.G., Lange C.A. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 2007, 67:4199-4209.
48. Najy A.J., Day K.C., Day M.L. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J. Biol. Chem. 2008, 283:18393-18401.
49. Ellis C., Moran M., McCormick F., Pawson T. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 1990, 343:377-381.
50. Moran M.F., Polakis P., McCormick F., Pawson T., Ellis C. Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol. Cell. Biol. 1991, 11:1804-1812.
51. Filvaroff E., Calautti E., McCormick F., Dotto G.P. Specific changes of Ras GTPase-activating protein (GAP) and a GAP-associated p62 protein during calcium-induced keratinocyte differentiation. Mol. Cell. Biol. 1992, 12:5319-5328.
52. Tsuruzoe K., Emkey R., Kriauciunas K.M., Ueki K., Kahn C.R. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol. Cell. Biol. 2001, 21:26-38.
53. Giovannone B., Scaldaferri M.L., Federici M., Porzio O., Lauro D., Fusco A., Sbraccia P., Borboni P., Lauro R., Sesti G. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diab. Metab. Res. Rev. 2000, 16:434-441.
54. Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P., Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001, 15:2099-2111.
55. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
56. Bae C.S., Lee S.T. The human PTK6 interacts with a 23-kDa tyrosine-phosphorylated protein and is localized in cytoplasm in breast carcinoma T-47D cells. J. Biochem. Mol. Biol. 2000, 34:33-38.
57. Vasioukhin V., Serfas M.S., Siyanova E.Y., Polonskaia M., Costigan V.J., Liu B., Thomason A., Tyner A.L. A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene 1995, 10:349-357.
58. Haegebarth A., Nunez R., Tyner A.L. The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. Cell Cycle 2005, 4:1239-1246.
59. Haegebarth A., Bie W., Yang R., Crawford S.E., Vasioukhin V., Fuchs E., Tyner A.L. Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol. Cell. Biol. 2006, 26:4949-4957.
60. Derry J.J., Prins G.S., Ray V., Tyner A.L. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003, 22:4212-4220.
61. Wang T.C., Jee S.H., Tsai T.F., Huang Y.L., Tsai W.L., Chen R.H. Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. Br. J. Dermatol. 2005, 153:282-289.
62. Petro B.J., Tan R.C., Tyner A.L., Lingen M.W., Watanabe K. Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol. 2004, 40:1040-1047.
63. Kasprzycka M., Majewski M., Wang Z.J., Ptasznik A., Wysocka M., Zhang Q., Marzec M., Gimotty P., Crompton M.R., Wasik M.A. Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. Am. J. Pathol. 2006, 168:1631-1641.
64. Wang W., Li Y., Li Y., Hong A., Wang J., Lin B., Li R. NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int. J. Cancer 2009, 124:521-530.
65. Harvell D.M., Richer J.K., Allred D.C., Sartorius C.A., Horwitz K.B. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology 2006, 147:700-713.
66. Rinaudo P., Schultz R.M. Effects of embryo culture on global pattern of gene expression in preimplantation mouse embryos. Reproduction 2004, 128:301-311.
67. Whitehead R.H., Robinson P.S., Williams J.A., Bie W., Tyner A.L., Franklin J.L. Conditionally immortalized colonic epithelial cell line from a Ptk6 null mouse that polarizes and differentiates in vitro. J. Gastroenterol. Hepatol. 2008, 23:1119-1124.
68. Haegebarth A., Perekatt A.O., Bie W., Gierut J.J., Tyner A.L. Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology 2009, 137:945-954.
69. Barker K.T., Jackson L.E., Crompton M.R. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997, 15:799-805.
70. Harvey A.J., Pennington C.J., Porter S., Burmi R.S., Edwards D.R., Court W., Eccles S.A., Crompton M.R. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am. J. Pathol. 2009, 175:1226-1234.
71. Schmandt R.E., Bennett M., Clifford S., Thornton A., Jiang F., Broaddus R.R., Sun C.C., Lu K.H., Sood A.K., Gershenson D.M. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol. Ther. 2006, 5:1136-1141.
72. Chen T., Boisvert F.M., Bazett-Jones D.P., Richard S. A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines. Mol. Biol. Cell 1999, 10:3015-3033.
73. Lin H.S., Berry G.J., Fee W.E., Terris D.J., Sun Z. Identification of tyrosine kinases overexpressed in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2004, 130:311-316.
74. Borczuk A.C., Gorenstein L., Walter K.L., Assaad A.A., Wang L., Powell C.A. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am. J. Pathol. 2003, 163:1949-1960.
75. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., Pham T.Q., Soriano R., Stinson J., Seshagiri S., Modrusan Z., Lin C.Y., O'Neill V., Amler L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11:8686-8698.
76. Coldren C.D., Helfrich B.A., Witta S.E., Sugita M., Lapadat R., Zeng C., Baron A., Franklin W.A., Hirsch F.R., Geraci M.W., Bunn P.A. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 2006, 4:521-528.
77. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
78. Ruhe J.E., Streit S., Hart S., Wong C.H., Specht K., Knyazev P., Knyazeva T., Tay L.S., Loo H.L., Foo P., Wong W., Pok S., Lim S.J., Ong H., Luo M., Ho H.K., Peng K., Lee T.C., Bezler M., Mann C., Gaertner S., Hoefler H., Iacobelli S., Peter S., Tay A., Brenner S., Venkatesh B., Ullrich A. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 2007, 67:11368-11376.
79. Kubo T., Kuroda Y., Kokubu A., Hosoda F., Arai Y., Hiraoka N., Hirohashi S., Shibata T. Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas 2009, 38:e200-e206.
80. Kubo T., Kuroda Y., Shimizu H., Kokubu A., Okada N., Hosoda F., Arai Y., Nakamura Y., Taniguchi H., Yanagihara K., Imoto I., Inazawa J., Hirohashi S., Shibata T. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 2009, 30:1857-1864.
81. Prickett T.D., Agrawal N.S., Wei X., Yates K.E., Lin J.C., Wunderlich J.R., Cronin J.C., Cruz P., Rosenberg S.A., Samuels Y. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 2009, 41:1127-1132.
82. Aubele M., Vidojkovic S., Braselmann H., Ritterswurden D., Auer G., Atkinson M.J., Tapio S., Hofler H., Rauser S., Bartlett J.M. Overexpression of PTK6 (breast tumor kinase) protein-a prognostic factor for long-term breast cancer survival-is not due to gene amplification. Virchows Arch. 2009, 455:117-123.
83. Meric F., Lee W.P., Sahin A., Zhang H., Kung H.J., Hung M.C. Expression profile of tyrosine kinases in breast cancer. Clin. Cancer Res. 2002, 8:361-367.
84. Chen H.Y., Shen C.H., Tsai Y.T., Lin F.C., Huang Y.P., Chen R.H. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol. Cell. Biol. 2004, 24:10558-10572.
85. Chakraborty G., Jain S., Kundu G.C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68:152-161.
86. Lecrone V., Li W., Devoll R.E., Logothetis C., Farach-Carson M.C. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 2000, 27:35-42.
87. Macri A., Versaci A., Lupo G., Trimarchi G., Tomasello C., Loddo S., Sfuncia G., Caminiti R., Teti D., Famulari C. Role of osteopontin in breast cancer patients. Tumori 2009, 95:48-52.
88. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr. Mol. Med. 2010, 10:71-81.
89. Ibrahim T., Flamini E., Mercantali L., Sacanna E., Serra P., Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 6:1406-1418.
90. Harvey A.J., Crompton M.R. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003, 22:5006-5010.
91. Ie Kim H., Lee S.T. Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J. Biochem. 2009, 146:133-139.
92. Zhao C., Yasui K., Lee C.J., Kurioka H., Hosokawa Y., Oka T., Inazawa J. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003, 98:18-23.
93. Aubele M., Auer G., Walch A.K., Munro A., Atkinson M.J., Braselmann H., Fornander T., Bartlett J.M. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br. J. Cancer 2007, 96:801-807.
94. Watson C.J., Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Semin. Cell Dev. Biol. 2008, 19:401-406.
95. Groner B., Lucks P., Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol. 2008, 19:341-350.
96. Wei L., Laurence A., O'Shea J.J. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin. Cell Dev. Biol. 2008, 19:394-400.
97. Walker S.R., Nelson E.A., Zou L., Chaudhury M., Signoretti S., Richardson A., Frank D.A. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res. 2009, 7:966-976.
98. Madson J.G., Lynch D.T., Tinkum K.L., Putta S.K., Hansen L.A. Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. Am. J. Pathol. 2006, 169:1402-1414.
99. Yim E.K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.Y. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
100. Richard S., Vogel G., Huot M.E., Guo T., Muller W.J., Lukong K.E. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene 2008, 27:548-556.
101. Nigg E.A. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 1997, 386:779-787.
102. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
103. Nahta R., Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
104. Bender L.M., Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front. Biosci. 2008, 13:3906-3912.
105. Singer C.F., Kostler W.J., Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim. Biophys. Acta 2008, 1786:105-113.
106. Born M., Quintanilla-Fend L., Braselmann H., Reich U., Richter M., Hutzler P., Aubele M. Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J. Pathol. 2005, 205:592-596.
107. Harvey A.J., Crompton M.R. The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs 2004, 15:107-111.
108. Rogers S.J., Box C., Chambers P., Barbachano Y., Nutting C.M., Rhys-Evans P., Workman P., Harrington K.J., Eccles S.A. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J. Pathol. 2009, 218:122-130.
109. Uckun F.M., Dibirdik I., Qazi S., Vassilev A., Ma H., Mao C., Benyumov A., Emami K.H. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg. Med. Chem. 2007, 15:800-814.